Read Analysis of Global Pericarditis Drugs Market 2019-2023Posted by Ruchi Walt on October 8th, 2019 Pericarditis is a condition, which involves the inflammation and irritation of pericardium or fibroelastic sac. The pericardium is a double-layered sac that separates the heart from the surrounding structures and protects it against the external vibrations and injuries. The treatment strategies of pericarditis have evolved with a better understanding of the immunopathogenic hypotheses. Anakinra is and an IL-1 beta recombinant receptor antagonist that has been recently proposed as a potential treatment option for patients with recurrent pericarditis and are resistant to colchicine and have corticosteroid dependency. It is a short-acting IL-1 antagonist and has recently gained focus on this therapeutic area. A recent study, anakinra-treatment of recurrent idiopathic pericarditis (AIRTRIP), randomized clinical trial, by Bructo A et. al. demonstrated the therapeutic efficacy of anakinra in patients with recurrent pericarditis with corticosteroid addiction and colchicine resistance. The study concluded that the use of anakinra was effective in reducing recurrent pericarditis episodes. However, more-detailed studies involving large patient pools are required to confirm the results and to access the safety and efficacy of the anakinra in long-term use. Hence, the advent of biologics will be a key trend in the global pericarditis drugs market to grow at a CAGR of 4.25% during the forecast period. Like it? Share it! More by this author |